Browse > Article
http://dx.doi.org/10.4250/jcu.2016.24.4.324

Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation  

Cho, Sang-Cheol (Department of Cardiology, Medical Genetics Clinic and Laboratory, Asan Medical Center, University of Ulsan College of Medicine)
Yoo, Han-Wook (Department of Pediatrics, Medical Genetics Clinic and Laboratory, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Jae Won (Department of Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Jang, Jeong Yoon (Department of Cardiology, Medical Genetics Clinic and Laboratory, Asan Medical Center, University of Ulsan College of Medicine)
Heo, Ran (Department of Cardiology, Medical Genetics Clinic and Laboratory, Asan Medical Center, University of Ulsan College of Medicine)
Song, Jong-Min (Department of Cardiology, Medical Genetics Clinic and Laboratory, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Journal of Cardiovascular Imaging / v.24, no.4, 2016 , pp. 324-328 More about this Journal
Abstract
A 71-year-old female who was diagnosed with nonobstructive hypertrophic cardiomyopathy since 1999 presented with dyspnea and severe edema on both legs. For the management of her symptom, cardiac surgery including tricuspid annuloplasty, Maze operation and right atrial reduction plasty was performed. During follow-up after cardiac surgery, a plasma ${\alpha}$-galactosidase activity was checked for the screening of Fabry disease and the result was around lower normal limit. DNA analysis was implemented for confirmation and it revealed a heterozygote ${\alpha}$-galactosidase mutation at exon 6 [c.901C>T (p.Arg301Ter)]. This case suggests that Fabry disease might be easily undetected, and clinical suspicion is critical.
Keywords
Fabry disease; Hypertrophic cardiomyopathy; Tricuspid regurgitation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, Russo MA, Frustaci A. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006;47:1663-71.   DOI
2 Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84.   DOI
3 Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G, Barbados FJ, Mangas A, Zamorano JL. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.   DOI
4 Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.   DOI
5 Koitabashi N, Utsugi T, Seki R, Okamoto E, Sando Y, Kaneko Y, Nagai R. Biopsy-proven cardiomyopathy in heterozygous Fabry's disease. Jpn Circ J 1999;63:572-5.   DOI
6 Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.   DOI
7 Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.   DOI
8 Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.   DOI
9 Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047-53.   DOI
10 Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002;40:1668-74.   DOI
11 Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144(5 Suppl):S20-6.   DOI
12 Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, Zeman J, Ledvinova J, Poupetova H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8.   DOI
13 Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.   DOI
14 Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7.   DOI
15 Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008;31:432-41.   DOI